Why a $49 weight-loss pill is rattling Novo Nordisk and Eli Lilly

Core Insights - Novo Nordisk and Eli Lilly are experiencing pressure in the GLP-1 market due to the introduction of a $49 weight-loss pill, which is a low-cost, compounded oral version of semaglutide [1] Company Impact - The launch of the low-cost semaglutide variant is expected to disrupt pricing strategies for Novo Nordisk and Eli Lilly, potentially leading to increased competition in the weight-loss medication sector [1] Industry Trends - The introduction of affordable alternatives in the GLP-1 market highlights a growing trend towards cost-effective solutions for weight management, which may influence consumer choices and market dynamics [1]